Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2002
05/21/2002US6391330 Proanthocyanidins and ascorbic acid composition for topical application to human respiratory and oral mucosa
05/21/2002US6391325 Use of nitrogen-containing complexing agents for deodorization and antimicrobial treatment of the skin and textile fibre materials
05/21/2002US6391323 Composition comprising, as active ingredients, chlorophyll, cod liver oil, camphor, and antiseptic agent selected from niaouli oil, thyme oil, and mixtures thereof, provided in pharmaceutically acceptable vehicle for topical application
05/21/2002US6391319 Cosmetic and dermatological emulsions comprising alkyl glucosides and increased electrolyte concentrations
05/21/2002US6391318 Composition comprising antigen and effective adjuvant amount of chitosan produced from chitin by deacetylation to degree of greater than 40% and having molecular weight between 10 kd and 500 kd
05/21/2002US6391311 Polypeptide comprising amino acid sequence at least about 80% identical to specified sequence, which has biological activity of promoting selective growth and/or survival of human umbilical vein endothelial cells in in vitro assay
05/21/2002US6391309 Composition made from plant matter enriched in at least two phytochemicals selected from isoflavones, lignans, saponins, sapogenins, catechins and phenolic acids; therapeutic treatment for female disorders
05/21/2002US6391308 Method of preparing and using isoflavones for the treatment of blood related illnesses
05/21/2002US6391299 Anti-factor IX/IXa antibodies
05/21/2002US6391298 Method of using PON-1 to decrease atheroma formation
05/21/2002US6391289 Use of sunscreen combinations comprising, as essential constituent, 4,4′-diarylbutadienes as photostable UV filters in cosmetic and pharmaceutical preparations
05/21/2002US6391287 Storage stable compositions
05/21/2002US6390821 Phosphorylation
05/21/2002CA2330480C Controlled release formulation of divalproex sodium
05/21/2002CA2268327C 3-carboxamide derivatives of 5h-pyrrolo[2,1-c][1,4]-benzodiazepines
05/21/2002CA2230750C Antiherpes peptidomimetic compounds
05/21/2002CA2223245C Catechol diethers derivatives useful as pharmaceutical agents
05/21/2002CA2216664C New n-substituted cyclical amines, their preparation process and the pharmaceutical compositions containing them
05/21/2002CA2153254C Cloning of enterokinase and method of use
05/21/2002CA2134077C 4-imidomethyl-1-¬2'phenyl-2'oxoethyl-|piperidines as serotonin 5ht2-antagonists, their preparation and use in therapy
05/21/2002CA2119932C Pressurized hydrofluoroalkane pharmaceutical aerosol compositions
05/21/2002CA2082636C Process for the preparation of sulfonylpristinamycin iib
05/21/2002CA2041417C Treatment of pancreatic disease with 15-keto-prostaglandin compounds
05/21/2002CA2039706C Method for preparing amino acid derivatives and therapeutical applications of same
05/21/2002CA1341359C Manufacturing process for a single-cell lifeform killing or growth inhibiting composition containing fluorine (f-) and lithium (li+)
05/17/2002CA2363147A1 Stable lactase compositions
05/17/2002CA2325041A1 Ultra-vit. plus
05/16/2002WO2002038607A2 A 'bach' g protein coupled receptor polypeptide and polynucleotide encoding this receptor
05/16/2002WO2002038600A2 C. elegans genes involved in viability and/or reproduction and uses thereof
05/16/2002WO2002038577A2 Extended release erythromycin derivatives
05/16/2002WO2002038575A1 Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipase
05/16/2002WO2002038571A1 Novel compounds
05/16/2002WO2002038570A1 Novel compounds
05/16/2002WO2002038568A1 Imidazo-triazine derivatives as ligands for gaba receptors
05/16/2002WO2002038563A2 Condensed pyrazindione derivatives as pde inhibitors
05/16/2002WO2002038561A1 Indolylmaleimide derivatives as protein kinase c inhibitors
05/16/2002WO2002038557A2 Benzoylbenzofurane derivatives for treatment of cardiac arrhythmia
05/16/2002WO2002038553A2 Triazole derivatives and their use as peroxisome proliferator activated receptor alpha agonists
05/16/2002WO2002038551A1 Pyrimidine derivatives and their use as neuropeptide y receptor ligands
05/16/2002WO2002038548A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
05/16/2002WO2002038547A1 Quinoline derivatives as nk-3 and nk-2 antagonists
05/16/2002WO2002038544A2 3-substituted oxindole beta 3 agonists
05/16/2002WO2002038543A2 3-substituted oxindole beta 3 agonists
05/16/2002WO2002038534A2 Substituted alkyldiamines as inhibitors of plasmepsin or related proteases
05/16/2002WO2002038528A1 Pleuromutilin derivatives with antimicrobial activity
05/16/2002WO2002038208A2 Device and method for the cessation of smoking
05/16/2002WO2002038186A1 Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides
05/16/2002WO2002038185A2 Injectable sustained release delivery system with loperamide
05/16/2002WO2002038184A1 Oral pharmaceutical composition containing a block copolymer
05/16/2002WO2002038181A2 Synergistic medicament containing aromatic agents and having an antagonistic, regenerative and/or protagonist decontamination effect
05/16/2002WO2002038180A1 High-density lipoprotein-cholesterol level elevating agent
05/16/2002WO2002038166A2 Ginseng berry extracts and pharmaceutical compositions therefrom
05/16/2002WO2002038160A1 Method for the treatment of inflammation
05/16/2002WO2002038159A1 Remedies for endometrial hyperplasia
05/16/2002WO2002038158A1 Improved treatment
05/16/2002WO2002038157A2 Inhibitors of thromboxane formation and action
05/16/2002WO2002038156A2 Methods of use of fluoroquinolone compounds against pathogenic helicobacter bacteria
05/16/2002WO2002038155A1 Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist
05/16/2002WO2002038154A1 Novel medicament compositions based on tiotropium salts and on salmeterol salts
05/16/2002WO2002038153A1 New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives
05/16/2002WO2002038151A1 Lipid peroxide-lowering compositions
05/16/2002WO2002038150A1 ACTIVATORS OF PEROXISOME PROLIFERATOR-ACTIVATED α AND β RECEPTORS AS MEDICAMENTS FOR TREATING SKIN DISORDERS HAVING IMMUNOLOGICAL CAUSES
05/16/2002WO2002038149A1 Remedies for keratoconjunctival diseases containing farnesyl acetate as the active ingredient
05/16/2002WO2002038148A1 ANTICANCER AGENTS, PERFUMES OR FOODS AND DRINKS CONTAINING φ-HYDROXYFATTY ACIDS
05/16/2002WO2002038147A1 Granular drug preparations containing branched amino acids and process for producing the same
05/16/2002WO2002038146A1 Mucosal immunomodulator and use thereof
05/16/2002WO2002038145A1 Compositions and methods for sedating, anaesthetising and euthanasing aquatic organisms
05/16/2002WO2002038144A2 The use of tiagabine for treatment of diabetic neuropathy and migraine
05/16/2002WO2002038143A2 Enhanced efficacy and safety of genotoxic therapy by p38 mapk modulation
05/16/2002WO2002038142A2 Serotonergic compositions and methods for treatment of mild cognitive impairment
05/16/2002WO2002038141A2 Compositions and methods for treatment of mild cognitive impairment
05/16/2002WO2002038140A2 Therapeutic uses for ip3 receptor-mediated calcium channel modulators
05/16/2002WO2002038139A1 Pharmaceutical preparation of percutaneous absorption type
05/16/2002WO2002038134A2 Multilayered supporting construction for plaster systems containing an active ingredient
05/16/2002WO2002038133A2 Compositions containing hydrolytically unstable compounds
05/16/2002WO2002038127A2 Particle formation methods and their products
05/16/2002WO2002038123A1 A skin cream composition
05/16/2002WO2002038106A2 Calcilytic compounds
05/16/2002WO2002038105A2 Novel polyamine analog-amino acid conjugates useful as anticancer agents
05/16/2002WO2002038077A2 L-histidine in ophthalmic solutions
05/16/2002WO2002037968A1 Methods for treating disorders of neuronal deficiency with bone marrow-derived cells
05/16/2002WO2002037937A2 Acid derivatives useful as serine protease inhibitors
05/16/2002WO2002037927A2 Compounds and methods for promoting smoking cessation
05/16/2002WO2002026727A3 Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai
05/16/2002WO2002022658A3 Muteins of the cgrp 1-7 peptide fragment and use thereof as nicotinic neuronal receptor enhancers
05/16/2002WO2002020488A3 Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor
05/16/2002WO2002020026A3 Treatment of drug resistant organisms with nitric oxide
05/16/2002WO2002020003A3 Use of carp inhibitors for the treatment of heart diseases
05/16/2002WO2002019994A3 The treatment of inflammatory disorders
05/16/2002WO2002017930A3 Glucocorticoid blocking agents for increasing blood-brain barrier permeability
05/16/2002WO2002017905A3 Treatment of burns
05/16/2002WO2002017892A3 Water-dispersible encapsulated sterols
05/16/2002WO2002011717A9 Cosmetics to support skin metabolism
05/16/2002WO2002010158A3 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
05/16/2002WO2002009681A3 A method for correcting the immune system of live body
05/16/2002WO2002008204A3 5-substituted pyrimidine derivatives of conformationally locked nucleoside analogues
05/16/2002WO2002007770A3 Polymeric conjugates of antitumor agents
05/16/2002WO2002003971A3 Pharmaceutical composition and method for the treatment of retroviral infections
05/16/2002WO2002002090A3 Inhibitors of copper-containing amine oxidases
05/16/2002WO2002000593A3 Compounds useful for the preparation of medicaments with phosphodiesterase iv inhibitory activity